How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Do you agree with the proposal to change recommendation 1.3.17 about the use of propranolol and topiramate for the prevention of migraine to make it a ‘consider’ recommendation alongside amitriptyline to better reflect the balance between the benefits and harms associated with the use of these medicines? If you disagree please provide a rationale.
The content on this page is not current guidance and is only for the purposes of the consultation process.

Amendment of recommendation 1.3.17 about the use of propranolol, topiramate and amitriptyline in Headaches in over 12s: diagnosis and management (NICE guideline CG150)

Closed for comments This consultation ended on at   Request commenting lead permission

Equalities

Medicines options for migraine prophylaxis are reduced in people who are pregnant, planning to become pregnant, or of childbearing potential unless the conditions of the Pregnancy Prevention Programme are fulfilled because of the risk of serious harm to the unborn child from topiramate.